“…Scientific information related to the vaccine and disease, such as safety, efficacy/effectiveness, clinical trials, and epidemiological studies, have always been reported [26,27], but immunological, virological, and antigenic studies are a more recent phenomenon [28][29][30]. Regarding economic studies, for example, costeffectiveness analyses of influenza vaccination were first reported in the US in 1997 [27], and later in 2003 in the Netherlands, together with mathematical modelling [31]. Following the 2009 pandemic, the use of these studies, jointly risk and uncertainty assessments, were frequently reported in European countries, the US, and Canada [32][33][34].…”